![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Human Genome Sciences Begins Dosing of Patients in Trial of CCR5 mAb
Human Genome Sciences Begins Dosing of Patients in Trial of CCR5 mAb
Human Genome Sciences has begun dosing patients in a Phase I clinical trial to evaluate the safety, tolerability and pharmacology of CCR5 mAb in patients who are infected with HIV-1, the retrovirus that causes AIDS.
CCR5 mAb (CCR5mAb004) is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5. The CCR5 receptor is known to be a key facilitator of infection with HIV-1.
The Phase I trial of CCR5 mAb is a randomized, placebo-controlled, dose-escalation, multicenter study in HIV-1 patients who are infected with HIV-1 and are not receiving concurrent antiretroviral therapy.
The primary objective is to evaluate the safety and tolerability of escalating doses of a single intravenous infusion of CCR5 mAb. The secondary objectives are to determine the pharmacokinetics of CCR5 mAb, and to assess its effect on plasma HIV-1 viral load and on CD4+ and CD8+ T-cell counts over time.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct